other material
confidence high
sentiment neutral
materiality 0.65
Gyre Therapeutics enters $50M at-the-market equity offering with Jefferies
GYRE THERAPEUTICS, INC.
- ATM agreement filed Nov 27, 2024; up to $50M of common stock may be sold.
- Jefferies LLC acts as sales agent; commission up to 3.0% of gross proceeds.
- Proceeds intended for R&D, manufacturing, scale-up, and general corporate purposes.
- Sales may be made on Nasdaq under effective S-3 shelf registration statement.